Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 4604

Next Previous
X
Search
Drug Profile

AZD 4604

Alternative Names: AZD-4604

Latest Information Update: 19 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Amides; Aniline compounds; Antiasthmatics; Fluorobenzenes; Indoles; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 13 Dec 2024 AstraZeneca plans a phase I trial for Asthma in Germany and United Kingdom (Inhalation, Powder) in January 2025 (NCT06732882)
  • 06 Dec 2024 Astrazeneca completes a phase I trial in Asthma in healthy Japanese and Chinese participants in United Kingdom (NCT06519968)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Asthma(In volunteers) in United Kingdom (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top